News Novo, Lilly sign MFN pricing deal with Trump administration The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.
News Lilly climbs on stellar GLP-1 drug sales gain Eli Lilly is celebrating a massive 54% increase in its third-quarter revenues to $17.6 billion, driven by its medicines for diabetes and obesity.
News GLP-1s from Novo, Lilly 'should be first-line in obesity' European doctors have said GLP-1 drugs are so effective in obesity that they should be the first choice drug treatment in almost all cases.
News High dose of Wegovy drives weight loss to 19% A triple dose of Novo Nordisk's GLP-1 agonist Wegovy has shown improved activity on weight loss in an obesity trial versus the current formulation.
News ICER says GLP-1s 'still have serious affordability issues' Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.
News FDA lends a hand to Novo, Lilly on illegal GLP-1 imports The FDA has set up a green list of overseas sources for GLP-1 ingredients to try to block imports of illegitimate and potentially unsafe materials.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.